Autres langues Monte Rosa Therapeutics, Inc.

Actions

GLUE

US61225M1027

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 27/07/2026			Varia. 5j.	Varia. 1 janv.
22,56 ^USD	-0,97 %		-3,92 %	+43,88 %

07/05	Monte Rosa Therapeutics, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
20/04	Monte Rosa Therapeutics présente au congrès annuel de l'AACR 2026 des données précliniques sur le potentiel de son dégradateur de colle moléculaire ciblant la cycline E1 (CCNE1) dans le traitement des tumeurs solides avec amplification de CCNE1	CI

Autres langues

02/07	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2500 Growth Benchmark
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell Microcap Value Benchmark Index
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 2000 Value Benchmark
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell Microcap Growth Benchmark Index
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2000 Growth Benchmark
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 3000E Growth Benchmark
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 3000E Value Benchmark
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 3000 Value Benchmark
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 3000 Growth Benchmark
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell Small Cap Comp Value Benchmark
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell Small Cap Comp Growth Benchmark
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 2500 Value Benchmark
02/06	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20/05	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
07/05	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
07/05	Monte Rosa Therapeutics: Q1 Earnings Snapshot
07/05	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q1 Revenue $4.2M, vs. FactSet Est of $11.4M
07/05	Monte Rosa Therapeutics : Corporate Presentation – May 2026
07/05	Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
05/05	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22/04	Monte Rosa Therapeutics : AACR 2026 – Selective targeting of CCNE1 using molecular glue degraders for the treatment of CCNE1 amplified cancers
20/04	Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
20/04	Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2026 on the Potential of its Cyclin E1-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
17/03	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025